Replies to post #186912 on Biotech Values

[DewDiligence]

…not sure why ABBV didn't PR the [GIFT-1] cirrhotic data…

All cirrhotic patients were in an open-label trial arm (arm “C” in the clinicaltrials.gov listing at https://clinicaltrials.gov/ct2/show/NCT02023099 ) that was independent from the predefined primary endpoint of the trial. The cirrhotic data will presumably be reported when the detailed data are at presented at a medical conference.

[DewDiligence]

Re: HCV Japan

…BMY with a good but not great regimen sold $200M+ last quarter [in Japan] (I think EU sales of daclatasvir were minimal).

The breakdown of BMY’s 4Q14 HCV sales of $207M was approximately 2/3 in Japan (where Daklinza is sold with Sunvepra) and approximately 1/3 in the EU (where Daklinza is sold separately and used with Sovaldi).